Lipid Stabilized Solid Drug Nanoparticles for Targeted Chemotherapy

2018 ◽  
Vol 10 (30) ◽  
pp. 24969-24974 ◽  
Author(s):  
Zhipeng Zeng ◽  
Pengfei Zhao ◽  
Lixin Liu ◽  
Xiaohu Gao ◽  
Hai-Quan Mao ◽  
...  
2019 ◽  
Vol 18 (15) ◽  
pp. 2078-2092 ◽  
Author(s):  
Mala Sharma ◽  
Chitranshu Pandey ◽  
Neha Sharma ◽  
Mohammad A. Kamal ◽  
Usman Sayeed ◽  
...  

Background: Nanotechnology pictures a breakthrough in the domain of cancer therapy owing to its novel properties and functions. This technology is quite amendable as it allows the scientists to engineer drug nanoparticles of dimensions 10nm – 500nm permitting them to pass via leaky vasculature of tumorigenic microenvironment with higher specificity, reduced cytotoxicity and effective release without any after effects. The central part of the review zooms onto the role of nanoparticles and their targeted delivery for the cure of cancer. Methods: The novel and various versatile nanoparticle platforms viz. polymeric (drug-conjugates, micelles, dendrimers), Lipid-based (liposomes, solid nanoparticle, nanostructured lipid carrier, lipid-polymer hybrid), and stimuli-sensitive (thermoresponsive, ultrasound, pH-responsive, hydrogel) etc. have been designed for a persistent, précised nanodrug delivery and the co-delivery of collegial drug conjugates leading to the formation of safer release of myriad of drugs for cancer chemoprevention. Results: The review concerns about tracing and detailing the drug delivery systems of cancer nanotechnology. Conclusion: Nanotechnology is bestowed with the design, depiction, fabrication, and application of nanostructures, and devices with their controlled delivery together with the imaging of the selected target site and drug release at the specific site of action.


FACE ◽  
2021 ◽  
pp. 273250162110051
Author(s):  
Steven Daws ◽  
Kongkrit Chaiyasate ◽  
Arshi Lehal

Ameloblastomas are uncommon tumors of the odontogenic epithelium standardly treated with radical resection. Recent studies of the genetic landscape of ameloblastoma have revealed the frequent presence of the BRAF V600E mutation, suggesting a possible role for targeted chemotherapy. We present the case of a primary mandibular ameloblastoma found in a 13-year-old female with confirmed BRAF V600E mutation. Prior to invasive surgical intervention she was treated for 8 weeks with the MEK inhibitor trametinib, but her tumor demonstrated little radiographic, clinical, or histologic response. Previous case reports have shown ameloblastoma in adult patients to be responsive to other agents targeting the MAPK pathway. Our observations in the presented case demonstrate the need for further research into the utility of targeted chemotherapy in ameloblastoma treatment.


2020 ◽  
Vol 31 (30) ◽  
pp. 305702
Author(s):  
Yuting Tang ◽  
Minglong Chen ◽  
Qian Xie ◽  
Lu Li ◽  
Lei Zhu ◽  
...  

Theranostics ◽  
2019 ◽  
Vol 9 (20) ◽  
pp. 5828-5838 ◽  
Author(s):  
Xiaojun Liu ◽  
Yingxue Sun ◽  
Shushen Xu ◽  
Xiaonan Gao ◽  
Fanpeng Kong ◽  
...  

2010 ◽  
Vol 7 (6) ◽  
pp. 705-719 ◽  
Author(s):  
Leena Peltonen ◽  
Hanna Valo ◽  
Ruzica Kolakovic ◽  
Timo Laaksonen ◽  
Jouni Hirvonen

1998 ◽  
Vol 114 ◽  
pp. A648
Author(s):  
P. Müller ◽  
P. Karle ◽  
R. Jesnowski ◽  
Robert Saller ◽  
S. Mitzner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document